The inferior quality drugs, folic acid and ferrous sulphate
tablets, were manufactured by an Indore-based pharmaceutical company and supplied by a Guwahati firm and distributed to the rural people.
State Health minister Tapan Chakraborty said all the Chief Medical Officers (CMO) of the state were sent urgent message to stop use of the two shoddy drugs when drug control authorities had confirmed the qualities of the drugs as inferior on December 5.
Chakraborty said no one would be spared if found guilty in procuring the drugs which might have bad implications and added an administrative inquiry had been ordered on Tuesday.
The opposition Congress has taken serious exception to the incident and threatened to go to court for redress.
"Only this incident proves how callous is the state health department. There is every possibility of harmful effect of the drugs on pregnant women and children", said party spokesman Ashok Sinha, who himself is a doctor.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
